A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Sponsor: Vertex Pharmaceuticals Incorporated
This PHASE3 trial investigates Cystic Fibrosis and is currently completed. Vertex Pharmaceuticals Incorporated leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Oct 2019 — Jun 2020 [monthly]
Completed PHASE3
-
Jun 2019 — Oct 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vertex Pharmaceuticals Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .